JP2023521436A5 - - Google Patents
Info
- Publication number
- JP2023521436A5 JP2023521436A5 JP2022562684A JP2022562684A JP2023521436A5 JP 2023521436 A5 JP2023521436 A5 JP 2023521436A5 JP 2022562684 A JP2022562684 A JP 2022562684A JP 2022562684 A JP2022562684 A JP 2022562684A JP 2023521436 A5 JP2023521436 A5 JP 2023521436A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- engineered
- cancer
- sirpg
- manipulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2005599.2 | 2020-04-17 | ||
| GBGB2005599.2A GB202005599D0 (en) | 2020-04-17 | 2020-04-17 | Modulation of t cell cytotoxicity and related therapy |
| PCT/EP2021/059989 WO2021209627A1 (en) | 2020-04-17 | 2021-04-16 | Modulation of t cell cytotoxicity and related therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521436A JP2023521436A (ja) | 2023-05-24 |
| JP2023521436A5 true JP2023521436A5 (https=) | 2024-04-26 |
Family
ID=70859980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562684A Pending JP2023521436A (ja) | 2020-04-17 | 2021-04-16 | Ｔ細胞細胞傷害性の調節および関連療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230158073A1 (https=) |
| EP (1) | EP4135725A1 (https=) |
| JP (1) | JP2023521436A (https=) |
| KR (1) | KR20230004643A (https=) |
| CN (1) | CN115697357A (https=) |
| AU (1) | AU2021255917A1 (https=) |
| BR (1) | BR112022020819A2 (https=) |
| CA (1) | CA3175622A1 (https=) |
| GB (1) | GB202005599D0 (https=) |
| IL (1) | IL297309A (https=) |
| MX (1) | MX2022012924A (https=) |
| WO (1) | WO2021209627A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022061115A1 (en) * | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| CN115058504B (zh) * | 2022-07-14 | 2025-07-04 | 广州医科大学 | 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用 |
| WO2025063257A1 (ja) * | 2023-09-22 | 2025-03-27 | 国立大学法人大阪大学 | 制御性ｔ細胞を製造する方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20140004174A (ko) | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| KR20170068504A (ko) * | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| JP7237449B2 (ja) * | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| KR102546839B1 (ko) * | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집 |
| WO2018106972A1 (en) * | 2016-12-07 | 2018-06-14 | La Jolla Institute For Allergy And Immunology | Compositions for cancer treatment and methods and uses for cancer treatment and prognosis |
| WO2018183921A1 (en) * | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| EP3622092A4 (en) * | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| CN110944652A (zh) * | 2017-06-12 | 2020-03-31 | 爱莫里大学 | T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途 |
-
2020
- 2020-04-17 GB GBGB2005599.2A patent/GB202005599D0/en not_active Ceased
-
2021
- 2021-04-16 US US17/919,135 patent/US20230158073A1/en active Pending
- 2021-04-16 CA CA3175622A patent/CA3175622A1/en active Pending
- 2021-04-16 CN CN202180041305.5A patent/CN115697357A/zh active Pending
- 2021-04-16 IL IL297309A patent/IL297309A/en unknown
- 2021-04-16 MX MX2022012924A patent/MX2022012924A/es unknown
- 2021-04-16 AU AU2021255917A patent/AU2021255917A1/en active Pending
- 2021-04-16 KR KR1020227039985A patent/KR20230004643A/ko active Pending
- 2021-04-16 EP EP21721004.6A patent/EP4135725A1/en not_active Withdrawn
- 2021-04-16 JP JP2022562684A patent/JP2023521436A/ja active Pending
- 2021-04-16 WO PCT/EP2021/059989 patent/WO2021209627A1/en not_active Ceased
- 2021-04-16 BR BR112022020819A patent/BR112022020819A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patel et al. | From concept to cure: The evolution of CAR-T cell therapy | |
| Lahiri et al. | Lung cancer immunotherapy: progress, pitfalls, and promises | |
| Han et al. | Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy | |
| Chang et al. | Immune selective pressure and HLA class I antigen defects in malignant lesions | |
| Sun et al. | MHC class II restricted neoantigen: a promising target in tumor immunotherapy | |
| Li et al. | CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety | |
| Comoli et al. | Development of adaptive immune effector therapies in solid tumors | |
| CN108392633B (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| Han et al. | Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors | |
| JP2023521436A5 (https=) | ||
| Wojtowicz et al. | Immunologic approaches to cancer prevention—current status, challenges, and future perspectives | |
| EP2839291B1 (en) | Multivalent breast cancer vaccine | |
| Rodriguez-Garcia et al. | T-cell target antigens across major gynecologic cancers | |
| JP2021535900A5 (https=) | ||
| JP7384896B2 (ja) | 主要組織適合遺伝子複合（ｍｈｃ）クラスｉｉ－発現癌細胞ワクチン、及び統合免疫応答を生じさせるための使用方法 | |
| JP2023518396A5 (https=) | ||
| Getts et al. | Synthetic T cell receptor-based lymphocytes for cancer therapy | |
| Wang et al. | Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy | |
| Li et al. | Immunotherapy in colorectal cancer: Statuses and strategies | |
| Li et al. | Precision sniper for solid tumors: CAR-NK cell therapy | |
| Arabi et al. | Advancements in colorectal cancer immunotherapy: from CAR-T cells to exosome-based therapies | |
| Lee et al. | Precision medicine-enabled cancer immunotherapy | |
| Bozorgi et al. | Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects | |
| Olivera et al. | Regional and intratumoral adoptive T-cell therapy | |
| Xue et al. | Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy |